billHR6319•Event Friday, November 28, 2025Analyzed

Benay Taub Lung Cancer Research Act

Neutral

Summary

HR6319 is an early-stage bill that establishes a Lung Cancer Task Force within NIH to study research disparities, funding levels, and screenings. It authorizes no funding and creates no direct revenue or cost impact on any publicly traded company. No market action is justified at this stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.Zero funding or spending authorized — no money trail for investors
2.Merely establishes a study task force with no binding recommendations
3.Early procedural stage with no committee action since Nov 2025
4.No identified tickers — no causal chain from bill text to any public company revenue

Market Implications

No market implications. HR6319 is a study-authorization bill with zero appropriations. It does not change the competitive dynamics, revenue outlook, or regulatory burden for any publicly traded company in lung cancer diagnostics, therapeutics, or screening. Retail investors should ignore this legislation until and unless it advances to a funding stage.

Full Analysis

On November 28, 2025, Rep. Gottheimer (D-NJ) introduced HR6319, the Benay Taub Lung Cancer Research Act. It was immediately referred to the House Committee on Energy and Commerce and has had no further action since referral. The bill is in its earliest legislative stage with zero committee hearings, markups, or votes. 2) The bill text creates a task force within NIH to examine lung cancer research disparities relative to other diseases, federal funding levels, and screening rates. It does not authorize or appropriate any dollar amount. The task force must report findings and recommendations to Congress within 180 days of enactment. There is no procurement mandate, no grant program, no tax credit, and no regulatory requirement directed at private companies. 3) Without funding or any binding directive, there are no structural winners or losers in publicly traded equities. Companies with exposure to lung cancer diagnostics, therapeutics, or screening technology — such as $LLY (oncology pipeline), $JNJ (lung cancer drugs), $BMY (Opdivo), $MRK (Keytruda), or screening firms like $ILMN (genomic sequencing) — have zero direct revenue channel from this procedural bill. 4) The bill has only 4 cosponsors, all junior members, and sits in the Commerce Committee. No companion bill exists in the Senate. Legislative velocity is minimal. 5) Remaining steps: committee consideration, potential markup, House vote, Senate introduction/passage, presidential signature. Given the procedural nature and zero funding authorization, this bill has effectively no timeline pressure or market relevance for at least 12-18 months, if ever.

Connected Signals

Matched on shared policy language across AI analyses, with ticker & timing weight

BillStrong LinkNeutral

Women and Lung Cancer Research and Preventive Services Act of 2025

Shared: Lung Cancer · Cancer Research · Lung41% match

BillBearish

Lung Cancer Screening Expansion Act of 2025

Shared: Lung Cancer · Screening · Lung23% match

BillNeutral

Women and Lung Cancer Research and Preventive Services Act of 2025

Shared: Lung Cancer · Cancer Research · Lung22% match

BillNeutral

Increasing Access to Lung Cancer Screening Act

Shared: Lung Cancer · Lung · Cancer22% match

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderOct 19, 2026

Advancing Women's Health to Improve Outcomes in All Phases of Life

This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.

$HOLX $MYGN $OGN $ILMN $ISRG $VRTX

6/10Source

Exec OrderSep 18, 2026

Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program

This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.

$INFY $WIT $CTSH $MSFT $AMZN $GOOGL

8/10Source

proclamationSep 8, 2026

Accelerating Access To Veterans' Benefits And Employment Opportunities

This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.

$LDOS $CACI $BAH $PLTR $SAIC

6/10Source

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →